Get informed when a big investor buys or sells
+ Follow0.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
CanSino Biologics (688185.SS) currently reports a ROE of 0.59%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore CanSino Biologics's ROE history and peer comparisons.
CanSino Biologics's ROE of 0.59% is lower than the Healthcare sector average of 13.1%. That is roughly 95.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but CanSino Biologics's current 0.59% should be judged against Healthcare norms (sector average: 13.1%) and against 688185.SS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 0.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for CanSino Biologics, and consider following 688185.SS for alerts when major investors trade the stock.
CanSino Biologics is classified in the Healthcare sector. On ROE, it currently shows 0.59% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 688185.SS with unrelated industries.